Vishin Ashish Patil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vishin Ashish Patil has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Ashwin Mali
Department of Industrial Pharmacy, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to Be University), Pune, India
3 shared publications - Ajay Shirsat
Hon. Shri Babanrao Pachpute Vichardhara Trust’s Group of Institutions, Faculty of Pharmacy
1 shared publication Anup Lal Yadav
School of Engineering and Technology, CGC University
1 shared publication- Durgacharan A. Bhagwat
Department of Pharmaceutics, Bharati Vidyapeeth College of Pharmacy, Kolhapur, India
1 shared publication - Jayashree Prasad
MIT Art Design and Technology University
1 shared publication - Mahesh Kumar Posa
Department of Pharmacology, School of Pharmaceutical Sciences, Jaipur National University, Jagatpura, Jaipur, Rajasthan, India
1 shared publication
Latest Publications
- 28 October 2026
- Published by Bentham Science Publishers Ltd. in Recent Advances in Drug Delivery and Formulation
- Vol. 20
SNEDDS and Cubosome as Advanced Lipid Nanocarriers for Natural Anticancer Bioactives: Mechanistic Insights, Challenges and Future Perspectives
Introduction: Natural bioactive compounds have great potential as anticancer agents. However, their clinical use, including curcumin, resveratrol, and thymoquinone, is limited due to poor solubility, instability, and low oral bioavailability. The goal of this review is to examine the impact of advanced lipid-based nanocarriers, especially self-nanoemulsifying drug delivery systems (SNEDDS) and cubosomes, on the enhancement of the bioavailability and anticancer activity of natural bioactive compounds. Methods: This review was conducted using a structured search strategy across databases. Original research articles, preclinical (in vitro/in vivo) studies, and peer-reviewed reviews reporting formulation, pharmacokinetic, and anticancer efficacy data for SNEDDS- or cubosome-based delivery of natural bioactive compounds were included. Results: This review indicates that SNEDDS enhance drug solubilization, intestinal absorption, and lymphatic transport, whereas cubosomes, owing to their unique bicontinuous cubic structure, enable higher drug-loading capacity, controlled release, and targeted drug delivery. Discussion: Both nanocarrier systems improve pharmacokinetic profiles, enhance intracellular drug delivery, and may help to overcome multidrug resistance, thereby improving the therapeutic efficacy of natural anticancer bioactive compounds. Emerging approaches like AI-assisted formulation design and lipidomic-guided optimization further support the development of more effective lipid-based delivery systems. Conclusion: SNEDDS and cubosomes are promising lipid-based nanocarriers that can effectively address the limitations of natural anticancer bioactive compounds by enhancing solubility, bioavailability, and therapeutic performance. The encouraging preclinical evidence supports their potential in cancer therapy. Further pharmacokinetic, safety, and well-designed clinical studies are required to facilitate their successful clinical translation.
- 28 October 2026
- Published by Bentham Science Publishers Ltd. in Recent Advances in Drug Delivery and Formulation
- Vol. 20
SNEDDS and Cubosome as Advanced Lipid Nanocarriers for Natural Anticancer Bioactives: Mechanistic Insights, Challenges and Future Perspectives
Introduction: Natural bioactive compounds have great potential as anticancer agents. However, their clinical use, including curcumin, resveratrol, and thymoquinone, is limited due to poor solubility, instability, and low oral bioavailability. The goal of this review is to examine the impact of advanced lipid-based nanocarriers, especially self-nanoemulsifying drug delivery systems (SNEDDS) and cubosomes, on the enhancement of the bioavailability and anticancer activity of natural bioactive compounds. Methods: This review was conducted using a structured search strategy across databases. Original research articles, preclinical (in vitro/in vivo) studies, and peer-reviewed reviews reporting formulation, pharmacokinetic, and anticancer efficacy data for SNEDDS- or cubosome-based delivery of natural bioactive compounds were included. Results: This review indicates that SNEDDS enhance drug solubilization, intestinal absorption, and lymphatic transport, whereas cubosomes, owing to their unique bicontinuous cubic structure, enable higher drug-loading capacity, controlled release, and targeted drug delivery. Discussion: Both nanocarrier systems improve pharmacokinetic profiles, enhance intracellular drug delivery, and may help to overcome multidrug resistance, thereby improving the therapeutic efficacy of natural anticancer bioactive compounds. Emerging approaches like AI-assisted formulation design and lipidomic-guided optimization further support the development of more effective lipid-based delivery systems. Conclusion: SNEDDS and cubosomes are promising lipid-based nanocarriers that can effectively address the limitations of natural anticancer bioactive compounds by enhancing solubility, bioavailability, and therapeutic performance. The encouraging preclinical evidence supports their potential in cancer therapy. Further pharmacokinetic, safety, and well-designed clinical studies are required to facilitate their successful clinical translation.
- 6 March 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (3) , 264
QbD-Guided RP-HPLC Method for Luteolin Featuring Full Factorial Design and Response Surface Optimization
- 6 March 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (3) , 264
QbD-Guided RP-HPLC Method for Luteolin Featuring Full Factorial Design and Response Surface Optimization
- Open Access
- 25 February 2026
- Published by Springer Nature in Research Square
Decision-Centric Explainable AI for QbD Optimization of Ultrasound-Triggered Drug- Loaded Microbubbles and Control Strategy Development
A decision-centric workflow was developed to link a QbD-defined design space with interpretable surrogate modeling for rapid selection of ultrasound-triggered doxorubicin-loaded chitosan microbubbles. A 15-run Box–Behnken design spanning chitosan, palmitic acid, and Pluronic F68 was used to quantify three critical quality attributes (CQAs)—mean size, encapsulation efficiency (EE), and burst release at 40 s (Burst40)—and to train response-specific surrogates evaluated by leave-one-out cross-validation (LOOCV). The DoE produced a broad performance envelope (size 2.35–4.85 µm; EE 60–82%; Burst40 55.6–95%) with clear composition-driven trade-offs, notably between EE and acoustic responsiveness. A regularized polynomial surrogate (PolyRidge) provided strong LOOCV performance for size (R²=0.885; RMSE = 0.264 µm) and EE (R²=0.871; RMSE = 2.18%), whereas Burst40 was only moderately predictable (R²=0.501; RMSE = 8.61%), consistent with threshold-like cavitation and microstructure sensitivity. Digital screening with multi-objective desirability and explainability (SHAP, permutation importance, partial dependence, LIME) shortlisted manufacturable candidates; experimental validation showed QbD/RSM was better calibrated for absolute size and EE, while both modeling approaches remained similarly limited for Burst40. Importantly, shortlisted formulations preserved suppressed baseline release and pronounced ultrasound-enhanced release, yielding trigger-dependent cytotoxicity and increased apoptotic commitment in MCF-7 cells.
- 25 February 2026
- Published by Springer Nature in Research Square
Open AccessDecision-Centric Explainable AI for QbD Optimization of Ultrasound-Triggered Drug- Loaded Microbubbles and Control Strategy Development
A decision-centric workflow was developed to link a QbD-defined design space with interpretable surrogate modeling for rapid selection of ultrasound-triggered doxorubicin-loaded chitosan microbubbles. A 15-run Box–Behnken design spanning chitosan, palmitic acid, and Pluronic F68 was used to quantify three critical quality attributes (CQAs)—mean size, encapsulation efficiency (EE), and burst release at 40 s (Burst40)—and to train response-specific surrogates evaluated by leave-one-out cross-validation (LOOCV). The DoE produced a broad performance envelope (size 2.35–4.85 µm; EE 60–82%; Burst40 55.6–95%) with clear composition-driven trade-offs, notably between EE and acoustic responsiveness. A regularized polynomial surrogate (PolyRidge) provided strong LOOCV performance for size (R²=0.885; RMSE = 0.264 µm) and EE (R²=0.871; RMSE = 2.18%), whereas Burst40 was only moderately predictable (R²=0.501; RMSE = 8.61%), consistent with threshold-like cavitation and microstructure sensitivity. Digital screening with multi-objective desirability and explainability (SHAP, permutation importance, partial dependence, LIME) shortlisted manufacturable candidates; experimental validation showed QbD/RSM was better calibrated for absolute size and EE, while both modeling approaches remained similarly limited for Burst40. Importantly, shortlisted formulations preserved suppressed baseline release and pronounced ultrasound-enhanced release, yielding trigger-dependent cytotoxicity and increased apoptotic commitment in MCF-7 cells.
- Open Access
- 30 January 2026
- Published by Informatics Publishing Limited in Journal of Natural Remedies
- p. 79-98
Herbal Pathways to Hormonal Balance: A Comprehensive Review on Natural Treatments for Polycystic Ovary Syndrome (PCOS)
Background: Polycystic Ovary Syndrome (PCOS) is one of the most prevalent endocrine-metabolic disorders affecting women of reproductive age. It is clinically characterised by polycystic ovarian morphology, chronic anovulation, and elevated androgen levels, leading to menstrual irregularities, infertility, hirsutism, and metabolic complications. Contributing factors such as insulin resistance, obesity, sedentary lifestyle, suboptimal diet, and psychological stress further exacerbate the condition. Limitations of conventional allopathic therapies have encouraged exploration of herbal alternatives with fewer side effects. Aim: To review the therapeutic potential of selected medicinal plants- Asparagus racemosus, Grifola frondosa, Lepidium meyenii, and Tinospora cordifolia in alleviating PCOS symptoms through their hypoglycaemic, anti-obesity, and hormone-modulating activities. Methods: Relevant literature from scientific databases was analysed for studies reporting the effects of these plant extracts on hormonal regulation, ovarian morphology, metabolic parameters, and insulin sensitivity in PCOS-induced models. Results: The reviewed plants demonstrated multiple beneficial mechanisms including anti-hyperandrogenic activity, modulation of estrogen and progesterone levels, improvement in insulin resistance, and reduction in ovarian weight and cyst formation. Phytoestrogen-rich extracts showed the ability to regulate serum sex hormones and support follicular development. Additionally, several plants exhibited hypoglycaemic and anti-obesity effects, contributing to better metabolic balance. Evidence also suggests their potential to stimulate ovulation and restore menstrual cyclicity. Conclusion: Herbal medicines from plants such as A. racemosus, G. frondosa, L. meyenii, and T. cordifolia demonstrate promising therapeutic effects in the management of PCOS. Their availability, multifaceted mechanisms, and lower side-effect profile make them attractive complementary options alongside lifestyle modifications. These findings highlight the potential of plant-based bioactive compounds in developing novel therapeutic strategies for PCOS, warranting further clinical investigation. Major Findings: The reviewed herbal extracts exhibited significant anti-hyperandrogenic effects, improved insulin resistance and metabolic balance, and supported restoration of normal ovarian function and ovulation. Phytoestrogen-rich plants showed effective modulation of sex hormones and reduction of ovarian cysts.
- 30 January 2026
- Published by Informatics Publishing Limited in Journal of Natural Remedies
- p. 79-98
Open AccessHerbal Pathways to Hormonal Balance: A Comprehensive Review on Natural Treatments for Polycystic Ovary Syndrome (PCOS)
Background: Polycystic Ovary Syndrome (PCOS) is one of the most prevalent endocrine-metabolic disorders affecting women of reproductive age. It is clinically characterised by polycystic ovarian morphology, chronic anovulation, and elevated androgen levels, leading to menstrual irregularities, infertility, hirsutism, and metabolic complications. Contributing factors such as insulin resistance, obesity, sedentary lifestyle, suboptimal diet, and psychological stress further exacerbate the condition. Limitations of conventional allopathic therapies have encouraged exploration of herbal alternatives with fewer side effects. Aim: To review the therapeutic potential of selected medicinal plants- Asparagus racemosus, Grifola frondosa, Lepidium meyenii, and Tinospora cordifolia in alleviating PCOS symptoms through their hypoglycaemic, anti-obesity, and hormone-modulating activities. Methods: Relevant literature from scientific databases was analysed for studies reporting the effects of these plant extracts on hormonal regulation, ovarian morphology, metabolic parameters, and insulin sensitivity in PCOS-induced models. Results: The reviewed plants demonstrated multiple beneficial mechanisms including anti-hyperandrogenic activity, modulation of estrogen and progesterone levels, improvement in insulin resistance, and reduction in ovarian weight and cyst formation. Phytoestrogen-rich extracts showed the ability to regulate serum sex hormones and support follicular development. Additionally, several plants exhibited hypoglycaemic and anti-obesity effects, contributing to better metabolic balance. Evidence also suggests their potential to stimulate ovulation and restore menstrual cyclicity. Conclusion: Herbal medicines from plants such as A. racemosus, G. frondosa, L. meyenii, and T. cordifolia demonstrate promising therapeutic effects in the management of PCOS. Their availability, multifaceted mechanisms, and lower side-effect profile make them attractive complementary options alongside lifestyle modifications. These findings highlight the potential of plant-based bioactive compounds in developing novel therapeutic strategies for PCOS, warranting further clinical investigation. Major Findings: The reviewed herbal extracts exhibited significant anti-hyperandrogenic effects, improved insulin resistance and metabolic balance, and supported restoration of normal ovarian function and ovulation. Phytoestrogen-rich plants showed effective modulation of sex hormones and reduction of ovarian cysts.
- 15 May 2025
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 83, 102542
Advanced microneedle arrays for transdermal antibiotic delivery
- 15 May 2025
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 83, 102542
Advanced microneedle arrays for transdermal antibiotic delivery
- 10 May 2025
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 83, 102536
Colloidal drug delivery systems for infectious diseases of skin
- 10 May 2025
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 83, 102536
Colloidal drug delivery systems for infectious diseases of skin